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Introduction
There is substantial evidence that central neurons use 5-hydroxytryptamine (5-HT) as their neurotransmitter (Kristic and Djurkovic, 1981; Dalton, 1986; Coote, 1990; Conner and Higgins, 1990; Valenta and Singer, 1990; Dreteler et al., 1991; Sporton et al., 1991; Bagdy et al., 1992) . This evidence includes that central injections of 5-HT or 5-HT receptor agonists alter mean arterial blood pressure (MAP), heart rate, and parasympathetic and sympathetic nerve activity (Baum and Shropshire, 1975; Yusof and Coote, 1988; Inoue and Bunag, 1989; Nosjean and Guyenet, 1991; Anderson et al., 1992) . For example, Inoue and Bunag (1989) reported that intracerebroventricular (i.c.v.) injection of 5-HT in anesthetized rats elicited a pressor response, which was associated with bradycardia and sympathoinhibition. This pressor response was attenuated by i.c.v. administration of the nonselective 5-HT receptor antagonist, methysergide, or systemic injection of an arginine vasopressin (AVP) V 1 -receptor antagonist (Inoue and Bunag, 1989) . The pressor response elicited by i.c.v. 5-HT in anesthetized rats is also attenuated by cervical spinal cord transection, adrenalectomy, or systemic injection of adrenergic blocking drugs or α-adrenoceptor antagonists and (Kristic and Djurkovic, 1980) . Furthermore, i.c.v. 5-HT causes a natriuresis that is dependent upon intact renal nerves (Montes and Johnson, 1990) . This suggests that i.c.v. 5-HT increases blood pressure by activation of the sympathetic nervous system although Inoue and Bunag (1989) found that i.c.v. 5 -HT did not increase splanchnic sympathetic nerve activity. However, a later study in anesthetized rats found that i.c.v. 5-HT increased renal sympathetic nerve activity via activation of central 5-HT 1A -receptors and stimulated AVP release via activation of central 5-HT 2 receptors (Anderson et al., 1992) .
It is also established that i.c.v. injections of 5-HT elicit pressor responses and bradycardia in conscious rats (Dalton, 1986; Sukamoto Microvascular Research 95 (2014) 116-123 et al., 1984; Montes and Johnson, 1990) . However, the peripheral hemodynamic mechanisms, which underlie the arterial blood pressure responses elicited by i.c.v. 5-HT in conscious Sprague-Dawley rats, are unknown. As such, a major aim of this study was to examine the time-course of the effects of i.c.v. injection of 5-HT (10 μg) on vascular resistances in mesenteric, renal and hindquarter beds of conscious rats and to establish whether i.c.v. injection of methysergide (10 μg) blocks the responses. The dose of 5-HT (10 μg, which is approximately 25 nmol) was chosen on the basis that it produced robust and consistent changes in regional vascular resistances. The 25 nmol dose is within the range of doses (0.3 to 100 nmol) used by others in conscious rats (Dalton, 1986; Sukamoto et al., 1984; Montes and Johnson, 1990; Watts et al., 2012) .
Endothelium-derived nitric oxide (NO) and other NO-containing factors such as S-nitrosothiols (together referred to as nitrosyl factors) play essential roles in the regulation of vascular resistance (see Moncada et al., 1991; Davisson et al., 1996a; Lewis et al., 2006; Moncada and Higgs, 2006; Lima et al., 2010) . Moreover, we found that active sympathetic neurogenic vasodilation in the hindlimb of conscious rats is also mediated by the release of nitrosyl factors (Davisson et al., 1994 (Davisson et al., , 1996b Davisson et al., 1997) . We therefore sought to establish the role of nitrosyl factors in the hemodynamic responses produced by i.c.v. administration of 5-HT. In these studies, we examined the hemodynamic responses produced by the i.c.v. injection of 5-HT in rats pretreated systemically with a 25 μg/kg dose of the NO synthesis inhibitor, N G -nitro-L-arginine methylester (L-NAME) (Moncada et al., 1991) . This dose of L-NAME elicits robust hemodynamic responses, most likely by actions within microvasculature (see Davisson et al., 1996a ), but does not appear to act in the brain since it did not interfere with central processing of afferent input regulating hemodynamic function Possas and Lewis, 1997; Possas et al., 2006) .
Materials and methods

Animals
All procedures were in accordance with the National Institutes of Health (1986) Guides for the Care and Use of Laboratory Animals and were approved by the University of Iowa Animal Care and Use Committee. All studies were performed in conscious male Sprague-Dawley rats (Harlan, Inc., Madison, Wisconsin) weighing 300-350 g (n = 40). The rats were individually housed in and maintained on a daily 12 hour light/dark cycle with rat chow and tap water available ad libitum.
Implantation of i.c.v. cannulae, catheters and Doppler flow probes
The rats were anesthetized with acepromazine maleate (12 mg/kg, i.p.) and ketamine (120 mg/kg, i.p.) and placed in a stereotaxic apparatus (Kopf) for implantation of a guide cannula (20 gauge, 10 mm in total length) into the left cerebral ventricle. The guide cannula was placed into the ventricle and cemented into position using screws to anchor the injection assembly into the skull. An obturator, which protruded 0.5 mm past the tip of the guide cannula, was then inserted. Catheters (PE-50) were implanted into the left common carotid artery to measure pulsatile and mean (MAP) arterial blood pressure and heart rate, and into the right jugular vein to administer drugs. After catheterization, a midline laparotomy was performed and Doppler flow probes were placed on the superior mesenteric artery, left renal artery and lower abdominal aorta to measure mesenteric, renal and hindquarter blood flow velocities, respectively, and for the calculation of mesenteric, renal and hindquarter vascular resistances. The probes were sutured in place, and the leads and catheters were tunneled subcutaneously and exteriorized between the scapulae. The wounds were sutured closed. To protect the probe wires and polyethylene tubing while allowing animals unrestricted movement, the free ends of the catheters and Doppler leads were led through a stainless steel skin button spring swivel assembly that was mounted to a ring stand clamp and suspended above the cage. The skin button was attached to the skin incision in the scapular region using stainless steel sutures. Details of the Doppler technique, including construction of probes, reliability of the method for estimation of flow velocity, and quantitative determination of percent changes in resistances, have been described previously by Haywood Haywood et al. (1981) .
In vivo protocols
After a 7-day recovery period, the rats were connected to a Beckman Dynograph coupled pressure transducer (Cabe Lab, Inc.) and Doppler flowmeter (Bioengineering, University of lowa) for the recording of HR, PP, MAP and blood flows, respectively. The stylus was removed from the guide cannula positioned into the cerebral ventricle and a microinjection needle (25 gauge, 10.5 mm in total length) connected to a glass Hamilton micro syringe (5 μL) via PE-10 tubing was then inserted into the guide cannula. The syringe, tubing and needle were filled with solutions of the test agents. The rats were given several minutes to relax before the i.c.v. injections were given. In study 1, the time-course of effects of i.c.v. injections of artificial cerebrospinal fluid (aCSF, 2 μL) or 5-HT (10 μg in 2 μL of aCSF) on hemodynamic variables were determined. In study 2, the responses elicited by i.c.v. 5-HT (10 μg) were examined in rats which had received i.c.v. injections of aCSF (2 μI) or methysergide (10 μg) 10 min earlier. In study 3, the responses elicited by i.c.v. 5-HT (10 μg) were examined in rats pretreated with an intravenous injection of saline (150-200 μL) or L-NAME (25 μmol/kg). 5-HT was given 15-20 min after saline or L-NAME, when stable values had been reached. 
Statistical analyses
The data are presented as mean ± SEM. The single SEM value displayed on each dose-response curve in Figs. 2-4 were determined by the formula S.E. = (EMS/n) 1/2 where EMS is the error mean square term from the analysis of variance (ANOVA) and n is the number of rats in each of the experimental groups (see Davisson et al., 1996a) . The data were analyzed by repeated-measures ANOVA followed by Student's modified t-test with the Bonferroni correction for multiple comparisons between means using the EMS terms from the ANOVA (see Davisson et al., 1996a) .
Results
Hemodynamic effects of i.c.v. injections of 5-HT
Resting hemodynamic variables in the groups of conscious rats, which received i.c.v. injections of either aCSF or 5-HT are summarized in Table 1 . There were no between-group differences in these variables (P N 0.05, for all comparisons). A typical example of the time-course of effects of an i.c.v. injection of 5-HT on heart rate, MAP and regional blood flows in a conscious freely-moving rat is shown in Fig. 1 . This dose of 5-HT produced a minor pressor response, which was associated with bradycardia, increases in hindquarter and renal blood flows and a decrease in mesenteric flow. The time-course of the hemodynamic responses elicited by i.c.v. injection of aCSF or 5-HT is summarized in Fig. 2 . The injection of aCSF did not elicit responses. The i.c.v. injection of 5-HT did not affect MAP except for a minor decrease observed 10 min after injection. Despite the minor effects on MAP, i.c.v. 5-HT elicited an immediate fall in heart rate, which was sustained for 20 min. In addition, i.c.v. 5-HT produced prompt and pronounced increases in hindquarter blood flow and decreases in hindquarter vascular resistance. The vasodilation in the hindquarter bed lasted for 25 min. The i.c.v. injection of 5-HT produced more delayed but transient changes in renal blood flow and resistance. A small but statistically significant increase in renal blood flow and a decrease in renal resistance were observed at 10 min. The i.c.v. injection of 5-HT produced immediate and pronounced decrease in mesenteric blood flow and increases in mesenteric resistance. The vasoconstriction in the mesenteric bed was still evident 35 min after i.c.v. 5-HT.
Effects of i.c.v. methysergide on the hemodynamic responses produced by i.c.v. 5-HT
The effects of i.c.v. injection of methysergide (10 μg) on resting hemodynamic parameters are summarized in Table 2 . None of the hemodynamic values were altered by administration of the 5-HT receptor antagonist. The effects of i.c.v. 5-HT (10 μg) on hemodynamic parameters of rats pretreated with i.c.v. injections of aCSF or methysergide are summarized in Fig. 3 . As can be seen, pretreatment with methysergide prevented the hemodynamic responses elicited by 5-HT.
Effects of i.v. L-NAME on the hemodynamic responses produced by i.c.v.
5-HT
The effects of i.v. injection of saline or L-NAME (25 μmol/kg on resting parameters are summarized in Table 3 . Saline did not modify any of these parameters. L-NAME produced a marked increase in MAP and vascular resistances and a bradycardia. These responses reached their maximum within 10 min and remained at these levels for 30-45 min. The responses elicited by i.c.v. 5-HT (10 μg) on hemodynamic variables in conscious rats pretreated with either saline or L-NAME (25 μmol/kg) are summarized in Fig. 4 . As can be seen, i.c.v. 5-HT produced a minor pressor response in the L-NAME-treated rats, which was associated with a bradycardia of similar magnitude and duration to that observed in saline-treated rats. The pronounced hindquarter vasodilation produced by i.c.v. of 5-HT in saline-treated rats was not observed in L-NAME-treated rats. In addition, the transient 5-HT-induced vasodilation in the renal bed was also not observed in L-NAME-treated rats. The initial mesenteric vasoconstriction produced by i.c.v. 5-HT was enhanced in L-NAME-treated rats. The vasoconstrictor effects thereafter were equivalent in saline-or L-NAME-treated rats.
Discussion
In this study, the i.c.v. injection of 5-HT (10 μg) elicited a relatively rapid, pronounced and long-lasting bradycardia in conscious rats that was associated with a delayed and relatively minor and transient fall in MAP. The rapid and robust nature of the bradycardia raises the possibility that 5-HT acts at sites close to the third ventricle. It is also unlikely that the bradycardia is of baroreflex in origin since the baroreflex would lower heart rate in response to an increase in MAP. However, it is not implausible that ICV administered 5-HT (1) reaches brain nuclei that process baroreflex information thereby promoting both a bradycardia and hypotension, and/or (2) reaches brainstem nuclei that directly control autonomic output to the heart. For example, Sporton et al. (1991) found that microinjection of 5-HT 1A agonists into the dorsal motor nucleus of the vagus elicits bradycardia in anesthetized rats. Our finding that prior i.c.v. treatment with methysergide (which did not affect resting heart rate in itself) prevented the bradycardia elicited by i.c.v. 5-HT in conscious rats is consistent with findings in anesthetized rats (Inoue and Bunag, 1989) . Methysergide has multiple agonist and antagonist effects on 5-HT receptor sub-types (Hoyer et al., 1994; Boess and Martin, 1994; Saxena, 1995; Villalón and Centurión, 2007) . For example, methysergide is an agonist at 5-HT 1A receptors (Hoyer et al., 1994) but an antagonist of 5-HT 2A - (Egan et al., 1998; Knight et al., 2004) , 5-HT 2B - (Glusa and Pertz, 2000; Knight et al., 2004) and 5-HT 2C -receptors (Egan et al., 2000; Knight et al., 2004) . In addition, the ICV injection of quipazine, which is a 5-HT 2A and 5-HT 3 receptor agonist, increases heart rate in anesthetized rats (Knowles and Ramage, 1999) . As such, it is tempting to assume that the bradycardic responses elicited by i.c.v. 5-HT in our conscious rats are mediated via activation of 5-HT 2B -and/or 5-HT 2C -receptors.
The i.c.v. injection of 5-HT also produced changes in regional vascular resistances. These injections of 5-HT elicited a pronounced and long-lasting vasoconstriction in the mesenteric bed, a transient vasodilation in the renal bed and a pronounced and long-lasting vasodilation in the hindquarter bed. As such, it appears that the minimal effect of 5-HT on MAP is due to the counterbalancing influences of these opposing changes in vascular resistances. These findings differ to those of conscious Long-Evans rats in which ICV 5-HT (40 and 120 nmol/kg; approximately 10 to 12 nmol) elicited a substantial pressor response and renal vasoconstriction (unlike the minor falls in MAP and renal resistance observed in our Sprague-Dawley rats) Each value represents the mean ± SEM. Note that there were no between group differences in any parameter at the P b 0.05 level. Fig. 1 . A typical example of the effects of an i.c.v. injection of 5-HT (10 μg) on the heart rate (HR), mean (MAP) and pulsatile (PP) arterial blood pressures, and hindquarter (HQF), renal (RF) and mesenteric (MF) blood flows in a conscious freely-moving rat.
although there was a decrease in heart rate, a mesenteric vasoconstriction and a hindquarter vasodilation of differing magnitude and duration observed in our rats. Although, the differences in the responses to 5-HT could be due to strain differences in the rats used in the two studies, the findings do provide compelling evidence that ICV 5-HT can have dramatically different effects on the neurogenic tone of systemic vascular beds. In our study, the rapid onset of the mesenteric vasoconstriction and the hindquarter vasodilation upon i.c.v. injection of 5-HT suggest that the responses are initiated by actions at sites close to the ventricle (Brody et al., 1978; Hoffman and Phillips, 1976) . Smits and Struyker-Boudier (1976) found that microinjection of 5-HT into the anterior hypothalamic area causes an increase in MAP. This area, which lies close to the third ventricle, receives serotonergic input from the dorsal raphe nucleus (Coote, 1990) . Since the hemodynamic responses produced by i.c.v. 5-HT were sustained for 25-35 min, it is also likely that these responses may involve actions of 5-HT on midbrain or brainstem sites. For example, microinjections of 5-HT1 A receptor agonists into the raphe obscurus cause a pressor response in anesthetized rats (Dreteler et al., 1991) . In addition, intrathecal 5-HT produces both excitation and inhibition of sympathetic nerve activity (Yusof and Coote, 1988) . However, it is also known that activation of 5-HT1 A receptors in other midbrain/brainstem sites such as the dorsal raphe Fig. 2 . Time-course of effects of i.c.v. injections of either aCSF (2 μL, n = 8) or 5-HT (10 μg in 2 μL, n = 8) on mean arterial blood pressures (MAP), heart rates (HR), hindquarter (HQF), renal (RF) and mesenteric (MF) blood flows, and hindquarter (HQR), renal (RR) and mesenteric (MR) vascular resistances in conscious freely-moving rats. Each value is the mean ± SEM of the percentage changes in these parameters. *P b 0.05, significant response.
Table 2
The effects of i.c.v. methysergide (10 μg) on resting hemodynamic parameters in conscious rats.
Parameter Pre Post Δ (%change) HR (bpm) 342 ± 8 336 ± 8 −2 ± 2 MAP (mm Hg) 116 ± 4 118 ± 3 +1 ± 3 HQR (mm Hg/kHz) 32 ± 6 32 ± 4 0 ± 7 RR (mm Hg/kHz) 69 ± 8 70 ± 7 +1 ± 3 MR (mm Hg/kHz) 24 ± 5 27 ± 6 +10 ± 6
Each value represents the mean ± SEM of data from 4 rats. Note that there were no between group differences in any parameter at the P b 0.05 level. (Conner and Higgins, 1990) , raphe magnus and pallidus (Valenta and Singer, 1990 ) and rostral ventrolateral medulla (Nosjean and Guyenet, 1991) cause hypotension and sympathoinhibition.
Our observation that i.c.v. methysergide elicited minimal hemodynamic responses but prevented the hemodynamic responses produced by i.c.v. 5-HT in conscious rats is consistent with findings that Fig. 3 . Time-course of effects of i.c.v. 5-HT (10 μg) on mean arterial blood pressures (MAP), heart rates (HR), hindquarter (HQF), renal (RF) and mesenteric (MF) blood flows, and hindquarter (HQR), renal (RR) and mesenteric (MR) vascular resistances in conscious freely-moving rats which had received i.v. injections of either aCSF (n = 6) or methysergide (10 μg, n = 4). Each value is the mean ± SEM of the percentage changes in these parameters. *P b 0.05, methysergide versus aCSF.
Table 3
The effects i.v. injections of saline or L-NAME (25 μmol/kg) on resting cardiovascular parameters of conscious rat.
HR, beats/min 338 ± 14 342 ± 16 +1 ± 2 365 ± 8 262 ± 7 −28 ± 3* MAP, mm Hg 119 ± 5 120 ± 5 +1 ± 1 123 ± 8 150 ± 4 +24 ± 5* HQF, kHz 4.2 ± 0.7 4.3 ± 0.8 +2 ± 4 4.9 ± 0.8 2.5 ± 0.6 −52 ± 7* HQR, mm Hg/kHz 31 ± 7 32 ± 8 +4 ± 6 +34 ± 9 96 ± 28 +191 ± 58* RF, kHz 5.1 ± 0.9 4.9 ± 0.9 −4 ± 3 5.5 ± 2.4 3.3 ± 1.3 −45 ± 8* RR, mm Hg/kHz 46 ± 12 49 ± 10 +7 ± 8 70 ± 17 304 ± 122 +171 ± 42* MF, kHz 7.3 ± 1.4 7.4 ± 1.5 +1 ± 5 8.5 ± 1.8 4.7 ± 0.8 −42 ± 4* MR, mm Hg/kHz 17 ± 5 17 ± 6 0 ± 6 19 ± 3 37 ± 6 +107 ± 15* Each value represents the mean ± SEM of the values from the saline-treated (n = 7) and L-NAME-treated (n = 7) rats. *P b 0.05, significant response.
methysergide attenuated the cardiovascular responses elicited by i.c.v. injections of 5-HT in anesthetized rats (Inoue and Bunag, 1989) . Anderson et al. (1992) reported that i.c.v. injection of 5-HT in anesthetized rats increased renal sympathetic nerve activity via stimulation of central 5-HT 1A -receptors and stimulated AVP release via activation of central 5-HT 2 receptors. As mentioned above, methysergide is an agonist at 5-HT 1A receptors but an antagonist of 5-HT 2A -, 5-HT 2B -and 5-HT 2C -receptors. As such, it is tempting to assume that the hemodynamic responses elicited by i.c.v. 5-HT in conscious rats due to the activation of 5-HT 2 -receptors, with the exact nature of the subtypes of 5-HT 2 receptors to be determined. The different pattern of hemodynamic changes produced by i.c.v. 5-HT could result from several mechanisms. Montes and Johnson (1990) and Inoue and Bunag (1989) provided evidence that i.c.v. 5-HT increases MAP, in part, by the release of AVP. As such, the vasoconstriction in the mesenteric bed produced by i.c.v. 5-HT may be mediated by the release of AVP, which constricts these vessels by activation of AVP V 1 -receptors (see Share, 1988) . Moreover, there is now substantial evidence that the stimulation of AVP V 1 -receptors on vascular endothelial cells can produce vasorelaxation via the release of nitrosyl factors (see Yamada et al., 1993) . Consequently, the hindlimb vasodilation produced by i.c.v. 5-HT may involve the AVP-mediated release of nitrosyl factors from the vascular endothelium in this bed. Another possibility is that the hemodynamic effects of i.c.v. 5-HT are mediated by the release of adrenal catecholamines. The i.v. injection of the selective 5-HT 1A receptor agonist, 8-OH-DPAT, causes the release of epinephrine by the centrally-mediated increase in preganglionic input to the adrenal glands (Bagdy et al., 1992) . The systemic administration of epinephrine produces a pressor response, which is associated with marked vasoconstriction in the mesenteric and renal beds, but a pronounced vasodilation in the hindquarter bed (see Kooy and Lewis, 1996) . Therefore, except for the changes in resistance in the renal bed the hemodynamic effects of epinephrine are somewhat similar to those produced by 5-HT. In the present study, it was evident that the Fig. 4 . Time-course of effects of i.c.v. 5-HT (10 μg) on mean arterial blood pressures (MAP), heart rates (HR), hindquarter (HQF), renal (RF) and mesenteric (MF) blood flows, and hindquarter (HQR), renal (RR) and mesenteric (MR) vascular resistances in conscious freely-moving rats which had received i.v. injections of saline (n = 7) or L-NAME (25 μmol/kg, n = 7). Each value is the mean ± SE of the percentage changes in these parameters. *P b 0.05, L-NAME versus saline.
systemic injection of L-NAME prevented the hindlimb vasodilation produced by the i.c.v. injection of 5-HT. In contrast, we have reported that the NO synthesis inhibitor does not diminish the hindlimb vasodilation produced by the systemic injection of epinephrine (Davisson et al., 1994) . However, Gardiner et al. (1990) reported that L-NAME did partially attenuate the hindlimb vasodilation produced by the continuous infusion of epinephrine. Moreover, Gardiner et al. (1990) demonstrated that the infusion of a high dose of epinephrine produces a vasodilation in the renal bed which is attenuated by L-NAME. Consequently, it is possible that epinephrine derived from the adrenal glands may contribute to the hemodynamic responses produced by the central administration of 5-HT. The loss of ICV 5-HT-mediated vasodilation in the renal and especially the hindquarter beds of L-NAME-treated rats is unlikely to be due to diminished efficacies of endogenous neural-or endothelium-derived vasodilators since the vasodilator responses to NO-donors are if anything exaggerated in these beds in L-NAME-treated rats (see Davisson et al., 1994 Davisson et al., , 1996a Davisson et al., ,b, c, 1997 .
In light of evidence that central administration of 5-HT influences sympathetic nerve activity (Baum and Shropshire, 1975; Yusof and Coote, 1988; Montes and Johnson, 1990; Anderson et al., 1992 Anderson et al., , 1996 , it is tempting to assume that the hemodynamic effects elicited by i.c.v. 5-HT involve changes in autonomic outflow. Central injections of 5-HT produce sympathoinhibition and/or sympathoexcitation in conscious and anesthetized rats (Baum and Shropshire, 1975; Kristic and Djurkovic, 1980, Kristie and Djurkovic, 1981; Yusof and Coote, 1988; Montes and Johnson, 1990; Nosjean and Guyenet, 1991; Anderson et al., 1992 Anderson et al., , 1996 . Because the pressor response produced by i.c.v. 5-HT in anesthetized rats is attenuated by α-adrenoceptor antagonists and cervical transection of the spinal cord (Kristic and Djurkovic, 1980) it is likely that the mesenteric vasoconstriction produced by i.c.v. 5-HT is due to a centrally-mediated increase in sympathetic vasoconstrictor drive. Since i.c.v. 5-HT can also cause sympathoinhibition, we reasoned that the vasodilation observed in the renal and hindquarter beds may be due to the withdrawal of sympathetic vasoconstrictor drive. However, i.c.v. 5-HT-induced natriuresis in conscious rats is markedly attenuated by transection of efferent renal sympathetic nerves (Montes and Johnson, 1990) suggesting that central 5-HT causes an increase in renal sympathetic nerve activity. In addition, we provided evidence that activation of the lumbar sympathetic chain in conscious rats by air-jet stress elicits a pronounced vasodilation in the hindquarter bed (Davisson et al., 1994 (Davisson et al., , 1996b and that direct electrical stimulation of the lumbar sympathetic chain produces hindlimb vasodilation in anesthetized rats (Davisson et al., 1996c (Davisson et al., , 1997 . These vasodilator responses were diminished by systemic administration of the NO synthesis inhibitor, L-NAME (Davisson et al., 1994 (Davisson et al., , 1996a (Davisson et al., ,b,c, 1997 . Taken together, it is possible that the hindlimb vasodilation produced by i.c.v. of 5-HT is mediated by an active sympathetic vasodilator process. The finding that L-NAME inhibited the 5-HT-induced vasodilation in the renal bed suggests that these responses involve the release of nitrosyl factors within the vasculature.
Neuronal pathways in the brain synthesize and use nitrosyl factors as neurotransmitters and/or neuromodulators (see Dawson et al., 1992; Lipton et al., 1994; Do et al., 1996; Garthwaite, 2008; Virarkar et al., 2013; Wang and Golledge, 2013) . Therefore, it is important to consider the possibility that L-NAME abolished the hindlimb vasodilation in response to i.c.v. 5HT by actions in the brain or spinal cord. This is especially important since systemically administered L-NAME may have important actions in the central nervous system (see Ma et al., 1995) . Ma et al. (1995) reported that the systemic injection of L-NAME (10 mg/kg, i.v.) influenced the activity of neurons in the nucleus tractus solitarius (the majority were inhibited) and that superfusion of rat brain slices with L-NAME decreased the firing rate of neurons in this nucleus (Ma et al., 1995) . Therefore, it is possible that the loss of hindlimb vasodilation in rats treated with L-NAME may be due to the actions of the NOS inhibitor in the NTS. However, it was evident that L-NAME did not interfere with the ability of i.c.v. 5-HT to elicit bradycardia. In addition, i.c.v. 5-HT produced a pronounced vasoconstriction in the mesenteric bed of L-NAME-treated rats, despite the marked increase in resting mesenteric resistance produced by the NO synthesis inhibitor. This suggests that L-NAME did not interfere with the central actions of 5-HT or the central processing of autonomic outflow. We have also provided evidence that the systemic injection of a 25 μmol/kg dose of L-NAME did not interfere with central processing aortic depressor nerve or superior laryngeal afferent input Possas et al., 2006) . As such, it is unlikely that the ability of L-NAME to abolish the hindquarter vasodilation elicited by i.c.v. 5-HT involves actions in the brain.
Summary
Central neurons using 5-HT as their neurotransmitter play a major role in regulating hemodynamic (Watts et al., 2012) and chemosensory/ventilatory (Teran et al., 2014) control systems via many 5-HT receptor subtypes. Disorders within serotonergic pathways (e.g., altered 5-HT release and reuptake; receptor down-regulation) are implicated in the etiology of disorders of cardiovascular (Watts et al., 2012) and ventilatory (Hilaire et al., 2010) systems in humans, the interplay between these vital systems (Szczepanska-Sadowska et al., 2010) and in cardiorespiratory dysfunction in humans with sleep apnea Fenik and Veasey, 2003) . Moreover, many humans take drugs that interfere with the central processing of 5-HT (e.g., metabolism, re-uptake) and therefore affect hemodynamic status. Indeed, reports of such drugs altering hemodynamic status (e.g., hypertension) and altering hemodynamic responsiveness (e.g., orthostatic hypotension) in humans and animals (Watts et al., 2012) are common. As such, elaborating the effects of central administration of 5-HT on regional systemic vascular resistances in normal subjects (and especially whether there is uniformity or non-uniformity in the changes in vascular tone between the beds) would be an important first step in understanding the hemodynamic consequences of aberrant serotonergic signaling. Our study demonstrates that whereas i.c.v. 5-HT (10 μg) produced minor changes in MAP, it elicited bradycardia and differential changes in vascular resistances including pronounced and sustained vasoconstriction in the mesenteric bed and vasodilation in the hindquarter bed and a transient renal vasodilation. It appears that the vasodilator responses produced by the i.c.v. 5-HT are mediated by the release of nitrosyl factors within these beds. The hemodynamic pattern produced by the i.c.v. 5-HT is somewhat similar to that produced by air-jet stress (Davisson et al., 1994 (Davisson et al., , 1996b . This raises the possibility that serotonergic systems within the brain may play a role in regulating the hemodynamic responses of defense reactions.
